Bristol-Myers Squibb Company (0R1F.L)
| Previous close | 72.70 |
| Open | 72.71 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 74.25 - 75.64 |
| 52-week range | 57.97 - 81.40 |
| Volume | |
| Avg. volume | 354,443 |
| Market cap | 1.2B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 0.26 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif., April 22, 2024--Bristol Myers Squibb (NYSE: BMY) and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments. As part of the agreement, Cellares will optimize, automate, and
- Business Wire
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., April 08, 2024--KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with.....
- Business Wire
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J., April 06, 2024--Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT....
